This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults.
Researchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation.
This will help identify the most effective way for future patients to use VRN101099 in the treatment of solid tumors and cancers.
The main questions it aims to answer is:
1. Does food or a PPI change how the body absorbs a single dose of VRN101099?
2. Is a single dose of VRN101099 safe and well tolerated when taken with or without food or a PPI?
3. How is VRN101099 removed through urine when taken with or without food or a PPI?